Retrophin, inc. (RTRX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Nov'12Sep'12Aug'12Jun'12May'12Mar'12Feb'12Nov'11Aug'11May'11
Cash Flows From Operating Activities:
Net income (loss)

808

-30,259

-36,490

-38,701

-40,977

-7,455

-54,516

-22,329

-18,378

-17,618

-17,794

-13,229

-11,090

-8,603

-37,113

-13,403

11,216

-2,469

105,578

-25,527

39,655

-29,027

-17,980

11,804

-75,735

-12,592

-12,241

-4,922

-4,868

-

-3

-

-3

-

-3

-3,572

-4

-3

-3

-3

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5,656

5,290

5,376

4,841

4,901

4,879

4,798

4,643

4,348

4,468

4,615

4,437

4,284

4,182

4,095

3,967

3,891

3,975

3,881

3,757

1,779

1,858

1,850

1,565

127

56

53

53

52

51

-

35

-

37

-

0

-

-

-

-

Legal fee settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,179

0

2,967

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

517

-

336

448

350

-

348

354

413

-

28

949

376

-

372

647

532

-

664

655

499

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Accretion) amortization of discounts/premiums on investments, net

-138

9

199

237

343

367

-102

-291

-356

-366

-370

-315

-287

1,950

-187

-277

-389

398

0

0

0

-

-

56

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax benefit

-

-

-

-

-

-

-

-

-

-

-2,391

-3,356

-2,064

-

1,287

-7,216

-5,070

-

28,230

0

-40,021

-

-

-

65

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of notes receivable

-

-

-

-

-

-

-

-

-

0

0

326

325

322

320

645

640

1,267

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount and issuance costs

2,551

2,506

2,464

2,474

2,459

2,418

655

325

0

-

-

-

-

165

165

163

163

165

165

508

502

513

567

4

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Realized (gain) loss on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-400

0

107

1,805

169

370

4

433

-59

0

0

-

-

-

-

-

-

-

-

-

-

-

Gain upon divestiture of assets to Turing Pharmaceuticals

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

914

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-334

86

941

-6,711

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-157

-35

160

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for Inventory

420

2,114

-288

-547

189

832

1,247

-438

816

-

-

-

-

-

-

-

-

0

0

0

1,050

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share based compensation

5,910

4,497

4,661

5,676

6,271

4,854

4,760

5,501

4,659

5,582

6,960

7,239

7,093

7,068

7,748

7,493

6,793

7,152

8,181

4,994

5,573

6,663

3,204

2,628

3,404

-

-

128

159

-

-

-

-

1,408

-

1,535

-

-

-

-

Change in fair value of contingent consideration

-1,922

9,232

-702

3,353

-14,831

-10,797

16,601

2,159

3,627

8,332

4,429

3,284

3,344

-

5,256

2,790

2,695

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Legal accrual reversal

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Compensation in lieu of receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

407

-

0

-

0

-

0

-

-

-

-

Share based compensation - non-employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,640

-

2,647

-

1,003

-

-

-

-

Bargain purchase gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

485

48,578

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

-6,971

-

-1,562

-1,362

-1,405

-

-1,289

-1,318

-4,245

-

-332

361

-914

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory Reserve

-

-

-

-

-

-

-

-

-

-

-

-

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Write off of IPR&D intangible assets

0

-

0

0

25,500

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments from change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

427

1,122

113

0

90

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value Adjustment of Warrants

-

-

-

-

-

-

-

-

-

-

-

-

-1,260

-6,504

10,126

9,063

-14,340

-2,873

-29,991

29,418

36,753

9,510

-6,359

-32,978

53,613

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

25

66

45

2

-62

381

214

-124

-75

247

33

-144

-53

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share based payment - Technology license contingent fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,550

-

0

-

0

-

0

-

-

-

-

Change in estimated fair value of derivative financial instruments - warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,311

-546

2,942

-

-

-

-

0

-

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

61

1,195

1,593

2,436

-40

1,194

85

-545

-886

-881

621

-1,609

-3,076

3,546

-1,609

3,226

927

-1,036

2,032

3,305

203

3,283

3,075

1,572

28

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Inventory

958

2,905

-29

-1,088

170

1,345

995

-160

593

1,387

107

-362

574

-144

538

-128

302

-110

644

287

353

117

186

-20

-0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Tax receivable

18,788

-

-

-

-304

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current and non-current operating assets

-7,666

-

-472

476

9,625

-

2,820

-216

-421

-

3,735

-934

946

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,013

-946

1,492

547

-127

-1,479

428

1,276

-462

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

362

-16

112

-

-

36

-

72

-

-78

-

-

-

-

Fair value of services provided by related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-

-

-

-

3

Accounts payable and accrued expenses

-16,577

-

-1,343

9,408

-3,103

-

9,802

6,519

-9,330

-

3,883

1,168

-4,626

-

2,628

4,210

-3,560

4,551

2,245

-1,311

-2,106

6,840

7,218

4,968

1,577

1,000

1,529

3,062

-2,750

2,303

-

586

-

199

0

-110

-

0

0

0

Other current and non-current operating liabilities

-7,519

-

-417

-2,691

9,886

-

609

274

2,211

-

2,606

101

-146

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-29,155

-4,492

-14,121

-19,109

-20,492

-3,565

-3,899

-2,760

-14,734

-854

6,198

5,466

-3,407

-8,493

4,629

3,990

-3,567

-3,552

739

8,018

-6,594

-9,095

-15,500

-11,449

-9,805

-8,396

-2,405

-2,208

-4,578

-

0

-

0

-

-0

-1,222

0

-0

-0

-0

Cash Flows From Investing Activities:
Purchase of fixed assets

208

-91

265

2

19

0

126

562

39

-550

381

218

838

1,367

37

0

24

-13

6

4

25

82

157

257

166

94

12

2

6

16

-

4

-

0

-

2

-

-

-

-

Cash paid for intangible assets

4,406

4,071

3,952

3,386

3,961

3,866

3,719

3,172

8,217

3,490

3,354

2,801

3,477

2,864

2,751

2,306

2,575

1,737

2,774

1,549

948

-1

1

3,239

61

5,427

0

5

0

-

-

75

-

1,082

-

0

-

-

-

-

Investment - Equity

-

-

-

-

-

0

0

5,000

10,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale/maturity of marketable securities

49,200

78,300

64,800

43,010

72,990

66,634

32,601

36,641

26,924

37,674

32,886

35,500

8,440

66,891

32,735

42,379

17,495

5,000

4,695

0

282

4,241

367

280

1,604

4,007

377

0

0

-

-

-

-

-

-

-

-

-

-

-

Purchase of marketable securities

5,000

72,712

56,200

14,378

80,422

111,525

190,301

0

29,519

34,863

31,339

36,213

0

32,095

83,499

43,865

24,652

103,737

94,793

0

0

0

5,262

2,217

2,669

693

3,430

0

0

-

-

-

-

-

-

-

-

-

-

-

Purchase of amortizable intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Repayment of technology license liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,300

-

-

0

-

0

-

0

-

-

-

-

Proceeds from securities sold, not yet purchased

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,038

147

4,314

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Cash received upon sale of assets, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

145,100

0

3,311

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Securities sold, not yet purchased

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-324

-4,985

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Cash received upon divestiture of asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid upon acquisition, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

33,430

0

0

0

29,150

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash received in merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3

-

0

-

0

-

0

-

-

-

-

Payments made on behalf of affiliate

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

137

-

0

-

0

-

0

-

-

-

-

Loans made to stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Increase in note receivable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4

-

198

-

-

-

-

Net cash provided by (used in) investing activities

39,551

1,580

4,465

25,230

-11,412

-48,802

-161,545

27,907

-20,851

-103

-2,188

43,768

4,125

30,470

-6,052

-4,292

-9,756

-100,461

52,222

-1,553

-30,810

1,970

-2,063

-6,057

-31,112

1,264

-5,355

-8

-1,306

-130

-

-289

-

-1,079

-

-200

-

-

-

-

Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration

5,308

826

840

817

905

879

895

881

7,066

-907

1,752

2,186

1,068

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

0

-

-

-

-

Repayment of net amounts due to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

13

-

-

-

-

-

-

-

-

-

-

-

Payment of other liability

-

-

-

-

-

-

-

-

-

102

250

250

250

-

-

-

-

1,000

500

0

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of guaranteed minimum royalty

525

525

525

525

509

500

500

500

500

500

500

500

500

500

500

500

500

500

500

500

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Note Purchase Agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

91

-

0

-

838

-

-

-

-

Proceeds from Issuance of Warrants

-

-

-

-

-

1,031

2,134

1,532

608

0

3,645

0

0

-

-

-

-

103

3,786

66

520

61

0

4,297

4,039

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

60

674

627

13

304

209

3,489

2,634

4,256

392

4,692

1,039

1,964

1,791

653

791

781

1,581

2,568

2,512

157

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of note payable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

884

30

-

15

-

0

-

0

-

-

-

-

Investors' deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

-

0

-

0

-

0

-

-

-

-

Repurchase of 2019 convertible senior notes including premium

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

-

-

-

Proceeds received from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33

0

0

149,454

3,165

0

-3,165

40,000

-168

21,829

0

9,275

710

-

720

-

1,504

-

540

-

-

-

-

Purchase of treasury stock, at cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-0

2,257

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Repayment of stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-35

-

-

-

-

Net cash used in financing activities

-5,773

95

-738

-324

-1,110

525

230,955

3,085

-2,702

1,361

5,835

-1,897

146

-5,044

4,038

-1,917

-926

1,232

-40,111

1,106

139,375

-533

3,545

53,691

38,616

-280

20,883

0

8,377

787

-

731

-

1,504

-

1,414

-

-

-

-

Effect of exchange rate changes on cash

-40

65

-75

22

-21

-105

4

-44

10

-1

-120

59

4

174

125

112

-294

-10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

4,583

-2,752

-10,469

5,819

-33,035

-51,947

65,515

28,188

-38,277

403

9,725

47,396

868

17,107

2,740

-2,107

-14,543

-102,791

12,850

7,571

101,971

-7,658

-14,018

36,184

-2,301

-7,412

13,123

-2,216

2,492

9

-

-29

-

30

-

-8

-

-

-

-

Financing costs from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

299

9,201

-

-

-

3,164

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental Disclosure of Cash Flow Information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

28

5

-

9

-

0

-

0

-

-

-

-

Non-cash Investing and financing activities:
Reclassification of derivative liability to equity due to exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

14,064

9,300

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Present value of contingent consideration payable to sellers of Asklepion Pharmaceuticals LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued in connection with Cholbam acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Present value of contingent consideration payable to sellers of Manchester Pharmaceuticals LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

12,797

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Note payable entered into upon acquisition of Manchester Pharmaceuticals, LLC.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

31,282

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on securities sold, not yet purchased

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,374

-1,424

84

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Allocation of proceeds from issuance of common stock to registration payment obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

360

-

-

-

-

-

-

0

-

-

-

-

Unrealized gain (loss) on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,182

-18

537

-

-154

0

0

-

-

-

-

-

-

-

-

-

-

-

Cost incurred related to debt financing not yet paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,882

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Change in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

-0

-

0

-0

-0

-0